Oncotarget is an organisation that was started in 2010. The organisation was started because of the increasing reduction of quality in medical research journals. Patients were getting diagnosed with different ailments, but the available information was insufficient to guarantee their safety. Because of this, Mikhail Blagosklonny saw a huge gap which had to be filled. The rate at which cancer patients were visiting healthcare facilities was alarming and Oncotarget lacrosse camp.
Offering free medical journals
Potential researchers had insufficient funds to support their research works. It was a challenge to them to gain access to the new developments in the field of cancer. Cancer is one of the most unrelenting conditions in the world today. To solve the problem, Oncotarget offers the public free access to the journals where different diseases can be checked and Oncotarget on Facebook.
The experience of Mikhail Blagosklonny
Mikhail Blagosklonny is the current CEO of Oncotarget. For a long time, Mikhail Blagosklonny spent his resources and knowledge in trying to understand cancer and ageing. After several years of dedicated studies, Mikhail understood that there is a lot of information which the public needed to know about the conditions. From this motivation, Mikhail Blagosklonny looked for a few other friends who had rich backgrounds in research on different cancer conditions. The team came together to help the medical experts and other medical researchers gain free access to medical journals and more information click here.
The quality leadership
Under the leadership of Mikhail Blagosklonny, Oncotarget has been one of the most influential organisations. By the time that the organisation was started, it only had about 450 journals for the public. Most scientific researchers did not consider these journals because of their scarcity. With years of growth and development, the organisation can now afford to avail more than 40000 different journals on medicine. Most of these journals focus on cancer treatment, diagnosis and management. Mikhail Blagosklonny received a boost from other experts who shared the same concern. The team has been working together for last six years to produce quality resources that would be helpful to the public. Currently, the members of the organisation work together to produce the quality resources without having to rely on other researchers and learn more about Oncotarget.
More Visit: http://www.bioxbio.com/if/html/ONCOTARGET.html
Dr. Clay Siegall is the president and CEO of Seattle Genetics. Seattle Genetics is a biotechnology company that develops targeted therapy drugs. The company focuses on diseases where there has not been an improvement in the mortality rate with current drugs. Dr. Siegall was interviewed on Inspirery where he talked about the origins of Seattle Genetics and its business model. He said that he started the company after seeing the harsh treatment techniques that were being used in the treatment of cancer. He was asked how long it took for the company to become profitable. Clay Siegall answered that it was a decade after they went public.
Siegall said that company executives usually have to go through a lengthy process in order to land new clients. This involves many meetings and negotiations that can stretch for months. Siegall added that the company’s legal team was very competent. They had proved themselves over the years. Siegall said that hard work was the primary reason for his success. He quoted a letter from Darwin to Francis Galton where Darwin says that men differed only in work habits and not intellect. Siegall went on to state that passion and focus were the two key elements needed for success. Other things including intelligence and connections are secondary to these.
Siegall has worked with Seattle Genetics since 1998 when it was started. He played a huge role when the company was raising capital from private and public investors. They were able to develop the first antibody drug conjugate to be approved by the FDA with him as the leader. Siegall has also secured partnerships with other pharmaceutical companies such as GlaxoSmithKline. Clay Siegall was appointed to the board of directors of Mirna Therapeutics in 2013. Mirna is a biotech company that is involved in the research and development of micro-RNA therapies. Siegall was brought to the company as an outside director of the board. Siegall spoke at the time of the announcement and said that he was honored to become a part of Mirna. He stated that he was pleased with the company’s vision.
Mikhail Blagosklonny is an incredibly well-known name in the field of cancer research and oncological treatments and has contributed immensely to the field. He has been the scientist behind numerous outstanding discoveries that have changed the course of cancer treatments. He has been involved in the field of cancer research since the start of his career and has consistently been working to bring about change in the field. Soon after completing his medical education, he began working at a company known as Oncotarget. The company is one that was involved in the research of new treatments for people who have been diagnosed with cancer. This was a perfect fit for Mikhail Blagosklonny, and he proved to be an important part of the company. He founded numerous new methodologies which were soon after being used by doctors all around the world for the treatment of cancer. Through his research, he has changed the lives of numerous people all over the world, giving them new hope for a better life. He has helped alter the way doctors diagnose and treat their patients, and has offered them a good alternative which helps them tackle the problem without doing much harm to the patients.
Teaching has always been one of the more important aspects of Mikhail Blagosklonny’s career. He has always believed in helping impart knowledge to others in the field and inspiring the new age of doctors and researchers. One of the first professorship jobs that Mikhail Blagosklonny got was soon after he had passed out of medical school. He began teaching at New York Medical College and was employed as an oncological professor there. He was an important teacher there and was highly regarded by all the students who had the good fortune of being taught by him. He tried his best to inspire them to enter into the field of oncology and make a difference to the numerous people who were diagnosed with this deadly disease.Even though Mikhail Blagosklonny does not work at the New York Medical College anymore, he continues to live out his passion for teaching as a professor of oncology at the Roswell Park Cancer Institute.
He is the head of the oncological department at the Institute and uses his incredible amount of experience in the field to educate the future oncological surgeons and researchers of the country.Even though he is so well versed in the field of oncology, one of Mikhail Blagosklonny’s most prized researchers has been in another field of medicine altogether. He used to research the current treatments that doctors are using on their patients, and would analyze the drugs that were being used. It was at this time that Mikhail Blagosklonny soon made an astonishing discovery that the chemical Rapamycin had the property to help increase the lifespan of those who took it. The development was considered to be revolutionary in the field of medicine since there is not much evidence already pointing towards something that can help increase the lifespan of human beings. Visit his Facebook page : https://www.facebook.com/Oncotarget/